US Bancorp DE Has $130,000 Position in Vericel Co. (NASDAQ:VCEL)

US Bancorp DE lowered its position in Vericel Co. (NASDAQ:VCEL) by 22.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,365 shares of the biotechnology company’s stock after selling 704 shares during the quarter. US Bancorp DE’s holdings in Vericel were worth $130,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in VCEL. Fisher Asset Management LLC lifted its stake in shares of Vericel by 16.3% during the 4th quarter. Fisher Asset Management LLC now owns 170,500 shares of the biotechnology company’s stock worth $9,362,000 after buying an additional 23,937 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Vericel by 13.6% during the 4th quarter. Mutual of America Capital Management LLC now owns 150,141 shares of the biotechnology company’s stock worth $8,244,000 after buying an additional 17,922 shares during the last quarter. GW&K Investment Management LLC lifted its stake in shares of Vericel by 2.4% during the 4th quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company’s stock worth $69,953,000 after buying an additional 30,180 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Vericel during the 4th quarter worth about $956,000. Finally, Oppenheimer Asset Management Inc. lifted its stake in shares of Vericel by 3.3% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 16,367 shares of the biotechnology company’s stock worth $899,000 after buying an additional 517 shares during the last quarter.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Stephens restated an “overweight” rating and set a $65.00 target price on shares of Vericel in a research note on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research note on Friday, February 28th. BTIG Research lifted their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Truist Financial reiterated a “buy” rating and issued a $61.00 price objective (down previously from $67.00) on shares of Vericel in a research note on Monday, March 3rd. Finally, Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $62.29.

Vericel Stock Down 0.0 %

VCEL stock opened at $45.38 on Monday. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $63.00. The firm has a market cap of $2.27 billion, a P/E ratio of 756.46 and a beta of 1.78. The company’s 50-day moving average price is $55.59 and its two-hundred day moving average price is $51.84.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now directly owns 26,595 shares of the company’s stock, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Dominick Colangelo sold 26,592 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the completion of the transaction, the chief executive officer now directly owns 259,997 shares in the company, valued at approximately $11,902,662.66. This represents a 9.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock valued at $1,683,582 in the last ninety days. 7.20% of the stock is currently owned by company insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.